- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
ARS Pharmaceuticals Inc (SPRY)
ARS Pharmaceuticals Inc stock price live, this page displays NASDAQ SPRY stock exchange data. View the SPRY premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the ARS Pharmaceuticals Inc real time stock price chart below.
What Is the ARS Pharmaceuticals Inc Stock Price Today?
The ARS Pharmaceuticals Inc stock price today is 17.52.
What Is the Stock Symbol for ARS Pharmaceuticals Inc?
The stock symbol for ARS Pharmaceuticals Inc is ""SPRY.""
What Stock Exchange Does ARS Pharmaceuticals Inc Trade On?
ARS Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is ARS Pharmaceuticals Inc a Good Stock to Buy?
Determining whether ARS Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SPRY quote. (ISIN: US82835W1080)
What Is the ARS Pharmaceuticals Inc Stock Price Today?
The ARS Pharmaceuticals Inc stock price today is 17.52.
What Is the Stock Symbol for ARS Pharmaceuticals Inc?
The stock symbol for ARS Pharmaceuticals Inc is ""SPRY.""
What Stock Exchange Does ARS Pharmaceuticals Inc Trade On?
ARS Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is ARS Pharmaceuticals Inc a Good Stock to Buy?
Determining whether ARS Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SPRY quote. (ISIN: US82835W1080)
NASDAQ
Currency in USD
17.52
-0.13(-0.74%)
Real-time Data·
Fair Value
An estimate of a ARS Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
17.52
17.90
52 wk Range
9.67
18.90
SPRY Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
SPRY is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a ARS Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
17.5217.90
52 wk Range
9.6718.90
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SPRY Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a ARS Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
32.00
Upside
+82.65%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to drop this year
- Ars pharma CCO Karas sells $240k in SPRY stock
- Investing.com
- Deerfield funds sell SPRY stock worth $13.7 million
- Investing.com
- Deerfield funds sell SPRY stock worth $13.7 million
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
ARS Pharmaceuticals Inc Company Profile
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.
ARS Pharmaceuticals Inc Earnings Call Summary for Q1/2025
- Q1 2025 revenue of $8M beats forecast, driven by successful NEFI launch; net loss of $33.9M or $0.35 per share
- Stock falls 3.67% premarket despite revenue beat; market cap at $1.31B with strong financial health score of 3.27
- Company projects $210-220M operating expenses for 2025; anticipates sales inflection in Q3 with peak in Aug-Sep
- NEFI gains traction with 13,000 prescriptions; company aims to cover 80% of commercial lives by Q3
- International launches planned from mid-2025 to early 2026; new DTC campaign 'Hello NEFI, Goodbye Needles' launched
Last Updated: 14/05/2025, 14:20
Read Full TranscriptCompare SPRY to Peers and Sector
Metrics to compare | SPRY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSPRYPeersSector | |
|---|---|---|---|---|
P/E Ratio | −110.4x | −2.9x | −0.5x | |
PEG Ratio | −1.62 | −0.05 | 0.00 | |
Price/Book | 7.5x | 2.7x | 2.6x | |
Price / LTM Sales | 17.8x | 8.7x | 3.3x | |
Upside (Analyst Target) | 68.4% | 81.3% | 43.4% | |
Fair Value Upside | Unlock | 15.1% | 7.1% | Unlock |
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 32.00
(+82.65% Upside)
Earnings
Latest Release
May 14, 2025
EPS / Forecast
-0.35 / -0.34
Revenue / Forecast
7.97M / 7.48M
People Also Watch
FAQ
What Stock Exchange Does ARS Pharmaceuticals Trade On?
ARS Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for ARS Pharmaceuticals?
The stock symbol for ARS Pharmaceuticals is "SPRY."
What Is the ARS Pharmaceuticals Market Cap?
As of today, ARS Pharmaceuticals market cap is 1.72B.
What Is ARS Pharmaceuticals's Earnings Per Share (TTM)?
The ARS Pharmaceuticals EPS (TTM) is -0.16.
When Is the Next ARS Pharmaceuticals Earnings Date?
ARS Pharmaceuticals will release its next earnings report on 05 Nov 2025.
From a Technical Analysis Perspective, Is SPRY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has ARS Pharmaceuticals Stock Split?
ARS Pharmaceuticals has split 0 times.
How Many Employees Does ARS Pharmaceuticals Have?
ARS Pharmaceuticals has 158 employees.
What is the current trading status of ARS Pharmaceuticals (SPRY)?
As of 08 Aug 2025, ARS Pharmaceuticals (SPRY) is trading at a price of 17.52, with a previous close of 17.65. The stock has fluctuated within a day range of 17.52 to 17.90, while its 52-week range spans from 9.67 to 18.90.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.